{
    "clinical_study": {
        "@rank": "107757", 
        "acronym": "BRIGHTEN", 
        "arm_group": {
            "arm_group_label": "Darbepoetin alfa"
        }, 
        "brief_summary": {
            "textblock": "This is an observational clinical research on patients with chronic kidney disease who are\n      not on hemodialysis and receiving darbepoetin alfa to treat diagnosed renal anemia; the\n      major objective is to explore novel erythropoiesis stimulating agent (ESA) response index in\n      association with deterioration of renal function as well as occurrence of cardiovascular\n      disease events."
        }, 
        "brief_title": "Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents", 
        "condition": [
            "Renal Anemia", 
            "Chronic Kidney Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Anemia", 
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients who are planning to start treatment with darbepoetin alfa within 8 weeks\n             after enrollment and not receiving any ESAs during 12 weeks before enrollment,\n\n          2. Patients with eGFR <60 mL/min/1.73m2 at the latest examination performed within 8\n             weeks before enrollment,\n\n          3. Patients with a hemoglobin level <11.0 g/dL at the latest examination performed\n             within 8 weeks before enrollment,\n\n          4. Patients aged at least 20 years or older at the time of providing informed consent,\n\n          5. Patients who voluntarily provided written informed consent to participate in the\n             study.\n\n        Exclusion Criteria:\n\n          1. Patients who are planning to start hemodialysis or to have a renal transplant within\n             24 weeks after enrollment,\n\n          2. Patients with malignant tumor, hematological disease, or hemorrhagic lesions,\n\n          3. Patients with hypersensitivity to ESA or any ingredient thereof,\n\n          4. Pregnant, lactating or possibly pregnant women or those who wish to become pregnant\n             during the study period,\n\n          5. Patients who are participating in other clinical study,\n\n          6. Patients who are assessed as not eligible for the study by the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Chronic renal disease patients without dialysis who are diagnosed with renal anemia and\n        are administered darbepoetin alfa at enrollment"
            }
        }, 
        "enrollment": {
            "#text": "2000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02136563", 
            "org_study_id": "TRIGU1318", 
            "secondary_id": "UMIN000013464"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Darbepoetin alfa", 
                "Hematinics"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic kidney disease", 
            "Erythropoiesis stimulating agent response index", 
            "Hyporesponsive anemia to erythropoiesis stimulating agent", 
            "Observational study"
        ], 
        "lastchanged_date": "May 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nagoya", 
                    "country": "Japan", 
                    "state": "Aichi", 
                    "zip": "466-8550"
                }, 
                "name": "Nagoya University Graduate School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_groups": "1", 
        "official_title": "oBservational Clinical Research In Chronic Kidney Disease Patients With Renal Anemia : Renal proGnosis in Patients With Hyporesponsive Anemia To Erythropoiesis Stimulating Agents, darbepoetiN Alfa", 
        "other_outcome": {
            "measure": "Erythropoiesis resistance index (ERI)", 
            "safety_issue": "No", 
            "time_frame": "For ninety six weeks after starting to administer darbepoetin alfa"
        }, 
        "overall_official": {
            "affiliation": "Nagoya University Graduate School of Medicine", 
            "last_name": "Seiichi Matsuo", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Life science ethics committee, Nagoya University Graduate School of Medicine: Japan", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Deterioration of renal function", 
                "safety_issue": "Yes", 
                "time_frame": "For ninety six weeks after starting to administer darbepoetin alfa"
            }, 
            {
                "measure": "Cardiovascular disease events", 
                "safety_issue": "Yes", 
                "time_frame": "For ninety six weeks after starting to administer darbepoetin alfa"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02136563"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Declination rate of estimated glomerular filtration rate(eGFR)", 
                "safety_issue": "No", 
                "time_frame": "For ninety six weeks after starting to administer darbepoetin alfa"
            }, 
            {
                "measure": "Safety assessment for every adverse event resulting from darbepoetin alfa administration", 
                "safety_issue": "Yes", 
                "time_frame": "For ninety six weeks after starting to administer darbepoetin alfa"
            }
        ], 
        "source": "Translational Research Informatics Center, Kobe, Hyogo, Japan", 
        "sponsors": {
            "collaborator": {
                "agency": "Nagoya University Graduate School of Medicine", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Translational Research Informatics Center, Kobe, Hyogo, Japan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}